Participating clinicians were blinded to the RS results and assigned the patients to ET alone or ET plus CT (CET) based on clinicopathologic factors, including the local Ki-67 value, in their institutional multidisciplinary tumor boards, and re-evaluated the treatment decisions post-surgery when the RS results became available within a second round within the same institutional multidisciplinary tumor board. This evidence concerns the gene MKI67 and neoplasm.